IL6 and pulmonary fibrosis: Notably, the suppressive effect of SF-MSCs on circulating IL-6 at day 14, regarded as the late phase of BLM-induced pulmonary fibrosis, was extremely strong, resulting in levels as low as those in control mice without BLM treatment.